CSL Behring is among the world's largest fully integrated plasma collection companies. Through subsidiary CSL Plasma (formerly ZLB Plasma), the company collects plasma through dozens of facilities in the US and Germany. CSL Behring also develops plasma protein biotherapeutics to treat a range of health ailments, including bleeding disorders (such as hemophilia), immune system deficiencies, and respiratory disease (including emphysema). Biotherapeutics are also used in critical care settings for surgical and wound healing applications. CSL Behring is a subsidiary of Australian biopharmaceutical firm CSL Limited.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

AutoImmune Inc. is a biopharmaceutical company developing products to treat autoimmune and other cell-mediated inflammatory conditions. Several of these products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects.

MicroIslet, Inc. is a biotechnology company engaged in the research, development and commercialization of technologies in the field of transplantation therapy for people with conditions requiring cell-based replacement treatments, with a focus on type 1, or insulin-dependent diabetes. Islet transplantation technology, licensed from Duke University, along with the Company's developments, constitutes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet intends to continue its research and development efforts and to introduce products to the market.

Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California. Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, and allergy; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the Lap-Band System and the BIB BioEnterics Intragastric Balloon; and facial aesthetics products.Allergan company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG.

Garden of Life, Inc. Company manufactures and supplies nutritional supplements, specialty food items, and personal care products. Its supplements include weight management, digestive health, and immune-system support products. The company's Original Medicine division produces nutritional products for distribution by health practitioners; its other lines are sold through natural foods retailers. Many of Garden of Life's products are based on a program called The Maker's Diet which was created by company founder and chairman Jordan Rubin in 2000 after overcoming Crohn's disease. Garden of Life has agreed to be acquired by Atrium Innovations.

Nippon Kayaku Co., Ltd. company is divided into three primary business lines: functional chemicals, pharmaceuticals, and automotive safety parts (airbags, ignition parts). It also manufactures pesticides and herbicides. Its pharmaceuticals segment is focused on producing anti-cancer drugs and immunosuppressants as well as cardiovascular and neurological drugs (brand name and generics). Other products in its divisions include dyes, inflators for automobile airbags, industrial explosives, epoxy resins, and agricultural chemicals. Nippon Kayaku has offices, manufacturing plants, and laboratories in Japan, as well as operations in China, Germany, Taiwan, and the US.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Chimerix, Inc. company was founded in 2002 and is headquartered in Durham, North Carolina. Chimerix has developed technology to make molecules with therapeutic potential into oral drugs. Its lipid conjugate technology can modify drug compounds to mimic a particular lipid metabolite that is absorbed by the small intestine, thus protecting the compounds from being broken down in the stomach. Chimerix is using its technology to develop lead drug candidate CMX001 to fight smallpox infections or bad reactions to smallpox vaccinations. The development-stage firm is also targeting drug-resistant HIV and hepatitis.

Metabolex, Inc. was founded in 1991 and is based in Hayward, California. Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.